ArticleBMC pulmonary medicine2025
Bidirectional causal association and shared anti-inflammatory target of asthma and atopic dermatitis: a Mendelian randomization and colocalisation study.
Article in BMC pulmonary medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Global Prevalence of Asthma in Adults with Atopic Dermatitis and the Atopic Dermatitis-Asthma Association.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundTo investigate the causal relationship between asthma and atopic dermatitis (AD), and to identify potential therapeutic targets for their co-treatment.
methodsAll summary statistics were sourced from publicly available genome‑wide association studies. Two‑sample Mendelian randomization (MR) analysis was employed to assess the causal relationship between asthma and AD, as well as the causal effects of 91 circulating inflammatory proteins on both conditions. Rigorous sensitivity analyses were conducted to verify the robustness of the findings. Colocalisation analysis was employed to determine whether the exposure and outcome were driven by shared single nucleotide polymorphisms. Additionally, molecular docking was used to validate the interactions of natural active ingredients with interleukin-6 (IL-6).
resultsIn the discovery cohorts, the MR results revealed an estimated effect of asthma on AD (OR = 1.224, 95% CI = 1.172–1.278, P = 5.89e-20) and an estimated effect of AD on asthma (OR = 1.229, 95% CI = 1.167–1.294, P = 4.83e-15). The MR analysis of replication cohorts yielded consistent results. IL-6 was identified being associated with both asthma and AD. Colocalisation analysis revealed that a shared causal variant within the selected gene locus was significantly associated with IL-6 and AD. However, no evidence was found to support the association of the shared variant with AD and asthma, or with IL-6 and asthma. Four natural active ingredients that interact with IL-6 were identified through molecular docking. IL-6 and atractylenolide I exhibited the lowest binding energy (-7.50 kcal/mol).
conclusionOur study demonstrated a bidirectional genetic correlation between asthma and AD. IL-6 may represent a therapeutic target for the concurrent management of both conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.